TY - JOUR
T1 - Determinants of Carotid Wall Echolucency in a Cohort of European High Cardiovascular Risk Subjects
T2 - A Cross-Sectional Analysis of IMPROVE Baseline Data
AU - IMPROVE Study Group
AU - Frigerio, Beatrice
AU - Coggi, Daniela
AU - Bonomi, Alice
AU - Amato, Mauro
AU - Capra, Nicolò
AU - Colombo, Gualtiero I
AU - Sansaro, Daniela
AU - Ravani, Alessio
AU - Savonen, Kai
AU - Giral, Philippe
AU - Gallo, Antonio
AU - Pirro, Matteo
AU - Gigante, Bruna
AU - Eriksson, Per
AU - Strawbridge, Rona J
AU - Mulder, Douwe J
AU - Tremoli, Elena
AU - Veglia, Fabrizio
AU - Baldassarre, Damiano
PY - 2024
Y1 - 2024
N2 - Echolucency, a measure of plaque instability associated with increased cardiovascular risk, can be assessed in both the carotid plaque and the plaque-free common carotid intima-media (IM) complex as a gray-scale median (plaque-GSM and IM-GSM, respectively). The impact of specific vascular risk factors on these two phenotypes remains uncertain, including the nature and extent of their influence. This study aims to seek the determinants of plaque-GSM and IM-GSM. Plaque-GSM and IM-GSM were measured in subjects from the IMPROVE study cohort (aged 54-79, 46% men) recruited in five European countries. Plaque-GSM was measured in subjects who had at least one IMT max ≥ 1.5 mm ( n = 2138), whereas IM-GSM was measured in all subjects included in the study ( n = 3188). Multiple regression with internal cross-validation was used to find independent predictors of plaque-GSM and IM-GSM. Plaque-GSM determinants were plaque-size (IMT max), and diastolic blood pressure. IM-GSM determinants were the thickness of plaque-free common carotid intima-media complex (PF CC-IMTmean), height, systolic blood pressure, waist/hip ratio, treatment with fibrates, mean corpuscular volume, treatment with alpha-2 inhibitors (sartans), educational level, and creatinine. Latitude, and pack-years code were determinants of both plaque-GSM and IM-GSM. The overall models explain 12.0% of plaque-GSM variability and 19.7% of IM-GSM variability. A significant correlation (r = 0.51) was found between plaque-GSM and IM-GSM. Our results indicate that IM-GSM is a weighty risk marker alternative to plaque-GSM, offering the advantage of being readily measurable in all subjects, including those in the early phases of atherosclerosis where plaque occurrence is relatively infrequent.
AB - Echolucency, a measure of plaque instability associated with increased cardiovascular risk, can be assessed in both the carotid plaque and the plaque-free common carotid intima-media (IM) complex as a gray-scale median (plaque-GSM and IM-GSM, respectively). The impact of specific vascular risk factors on these two phenotypes remains uncertain, including the nature and extent of their influence. This study aims to seek the determinants of plaque-GSM and IM-GSM. Plaque-GSM and IM-GSM were measured in subjects from the IMPROVE study cohort (aged 54-79, 46% men) recruited in five European countries. Plaque-GSM was measured in subjects who had at least one IMT max ≥ 1.5 mm ( n = 2138), whereas IM-GSM was measured in all subjects included in the study ( n = 3188). Multiple regression with internal cross-validation was used to find independent predictors of plaque-GSM and IM-GSM. Plaque-GSM determinants were plaque-size (IMT max), and diastolic blood pressure. IM-GSM determinants were the thickness of plaque-free common carotid intima-media complex (PF CC-IMTmean), height, systolic blood pressure, waist/hip ratio, treatment with fibrates, mean corpuscular volume, treatment with alpha-2 inhibitors (sartans), educational level, and creatinine. Latitude, and pack-years code were determinants of both plaque-GSM and IM-GSM. The overall models explain 12.0% of plaque-GSM variability and 19.7% of IM-GSM variability. A significant correlation (r = 0.51) was found between plaque-GSM and IM-GSM. Our results indicate that IM-GSM is a weighty risk marker alternative to plaque-GSM, offering the advantage of being readily measurable in all subjects, including those in the early phases of atherosclerosis where plaque occurrence is relatively infrequent.
U2 - 10.3390/biomedicines12040737
DO - 10.3390/biomedicines12040737
M3 - Article
C2 - 38672093
SN - 2227-9059
VL - 12
JO - Biomedicines
JF - Biomedicines
IS - 4
M1 - 737
ER -